{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:53:52Z","timestamp":1793314432793,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20759, 82441018, 12090022, 92259302, 82373438"],"award-info":[{"award-number":["U24A20759, 82441018, 12090022, 92259302, 82373438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["JC202301, JC202303, JC202406"],"award-info":[{"award-number":["JC202301, JC202303, JC202406"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520600"],"award-info":[{"award-number":["2024ZD0520600"]}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QMS20201101"],"award-info":[{"award-number":["QMS20201101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04341-y","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:05:35Z","timestamp":1773054335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A two-step scoring model incorporating visceral-to-subcutaneous fat ratio and systemic immunoinflammatory index for predicting cytokine release syndrome severity in patients with gastric cancer receiving Claudin18.2-targeted CAR-T cell therapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Meng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"4341_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric Antigen Receptor Therapy. N Engl J Med 379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169","journal-title":"N Engl J Med"},{"key":"4341_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","volume":"15","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n V, San Rom\u00e1n M, Pozas J et al (2024) Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol 15:1352805. https:\/\/doi.org\/10.3389\/fimmu.2024.1352805","journal-title":"Front Immunol"},{"key":"4341_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA et al (2021) CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther 12:81. https:\/\/doi.org\/10.1186\/s13287-020-02128-1","journal-title":"Stem Cell Res Ther"},{"key":"4341_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4341_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1079181","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Li P, Tian B, Kang X (2022) Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. Front Immunol 13:1079181. https:\/\/doi.org\/10.3389\/fimmu.2022.1079181","journal-title":"Front Immunol"},{"key":"4341_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23:943\u2013947. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028","journal-title":"Oncologist"},{"key":"4341_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/edbk_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ (2019) The other side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book 39:433\u2013444. https:\/\/doi.org\/10.1200\/edbk_238691","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4341_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W (2018) Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res 6:4. https:\/\/doi.org\/10.1186\/s40364-018-0116-0","journal-title":"Biomark Res"},{"key":"4341_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH (2018) Cancer-associated cachexia. Nat Rev Dis Primers 4:17105. https:\/\/doi.org\/10.1038\/nrdp.2017.105","journal-title":"Nat Rev Dis Primers"},{"key":"4341_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.18054","volume":"197","author":"I Roy","year":"2022","unstructured":"Roy I, Smilnak G, Burkart M et al (2022) Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol 197:71\u201375. https:\/\/doi.org\/10.1111\/bjh.18054","journal-title":"Br J Haematol"},{"key":"4341_CR11","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1007\/s00520-021-06639-2","volume":"30","author":"S Ding","year":"2022","unstructured":"Ding S, Cai L, Jin A, Zhou X, Yan J, Wang L, Zhao H, Wang T, Hu Y (2022) Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study. Support Care Cancer 30:3321\u20133327. https:\/\/doi.org\/10.1007\/s00520-021-06639-2","journal-title":"Support Care Cancer"},{"key":"4341_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clnesp.2021.10.015","volume":"46","author":"B Cucchiaro","year":"2021","unstructured":"Cucchiaro B, Weekes CE (2021) Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy. Clin Nutr ESPEN 46:60\u201365. https:\/\/doi.org\/10.1016\/j.clnesp.2021.10.015","journal-title":"Clin Nutr ESPEN"},{"key":"4341_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly LE, Power DG, O\u2019Reilly \u00c1 et al (2017) The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer 116:310\u2013317. https:\/\/doi.org\/10.1038\/bjc.2016.431","journal-title":"Br J Cancer"},{"key":"4341_CR14","doi-asserted-by":"publisher","first-page":"e21010-e","DOI":"10.1200\/JCO.2018.36.15_suppl.e21010","volume":"36","author":"SS Shachar","year":"2018","unstructured":"Shachar SS, Fried R, Shafran I, Moskovitz MT, Williams GR, Bar-Sela G, Reiner-Benaim AS, Wollner M (2018) Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo). J Clin Oncol 36:e21010-e. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e21010","journal-title":"J Clin Oncol"},{"key":"4341_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123243","author":"K Oura","year":"2023","unstructured":"Oura K, Morishita A, Manabe T et al (2023) Relationship between accurate diagnosis of sarcopenia and prognosis in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab combination therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15123243","journal-title":"Cancers (Basel)"},{"key":"4341_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2019.11.003","volume":"124","author":"L Hirsch","year":"2020","unstructured":"Hirsch L, Bellesoeur A, Boudou-Rouquette P et al (2020) The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer 124:170\u2013177. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.003","journal-title":"Eur J Cancer"},{"key":"4341_CR17","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1007\/s00520-020-05477-y","volume":"28","author":"U Oflazoglu","year":"2020","unstructured":"Oflazoglu U, Alacacioglu A, Varol U et al (2020) The role of inflammation in adjuvant chemotherapy-induced sarcopenia (Izmir Oncology Group (IZOG) study). Support Care Cancer 28:3965\u20133977. https:\/\/doi.org\/10.1007\/s00520-020-05477-y","journal-title":"Support Care Cancer"},{"key":"4341_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2021.111464","volume":"93","author":"Y Li","year":"2022","unstructured":"Li Y, Wang WB, Yang L et al (2022) The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy. Nutrition 93:111464. https:\/\/doi.org\/10.1016\/j.nut.2021.111464","journal-title":"Nutrition"},{"key":"4341_CR19","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","volume":"107","author":"DMC Dos Santos","year":"2022","unstructured":"Dos Santos DMC, Rejeski K, Winkelmann M et al (2022) Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Haematologica 107:2096\u20132107. https:\/\/doi.org\/10.3324\/haematol.2021.280189","journal-title":"Haematologica"},{"key":"4341_CR20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J et al (2022) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28:1189\u20131198. https:\/\/doi.org\/10.1038\/s41591-022-01800-8","journal-title":"Nat Med"},{"key":"4341_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J et al (2024) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03037-z","journal-title":"Nat Med"},{"key":"4341_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"4341_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007054","author":"M He","year":"2023","unstructured":"He M, Chen ZF, Zhang L et al (2023) Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-007054","journal-title":"J Immunother Cancer"},{"key":"4341_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH (2021) nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 18:203\u2013211. https:\/\/doi.org\/10.1038\/s41592-020-01008-z","journal-title":"Nat Methods"},{"key":"4341_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/0734-189X(85)90016-7","volume":"30","author":"S Satoshi","year":"1985","unstructured":"Satoshi S, Ab K (1985) Topological structural analysis of digitized binary images by border following. Comput Vision, Graph, Image Process 30:32\u201346. https:\/\/doi.org\/10.1016\/0734-189X(85)90016-7","journal-title":"Comput Vision, Graph, Image Process"},{"key":"4341_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000191","volume":"3","author":"J Garcia Borrega","year":"2019","unstructured":"Garcia Borrega J, G\u00f6del P, R\u00fcger MA, Onur \u00d6A, Shimabukuro-Vornhagen A, Kochanek M, B\u00f6ll B (2019) In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere 3:e191. https:\/\/doi.org\/10.1097\/hs9.0000000000000191","journal-title":"Hemasphere"},{"key":"4341_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"key":"4341_CR28","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","volume":"139","author":"J Gauthier","year":"2022","unstructured":"Gauthier J, Gazeau N, Hirayama AV et al (2022) Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood 139:3722\u20133731. https:\/\/doi.org\/10.1182\/blood.2021014497","journal-title":"Blood"},{"key":"4341_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","volume":"22","author":"JX Cao","year":"2020","unstructured":"Cao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX (2020) The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy 22:214\u2013226. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.015","journal-title":"Cytotherapy"},{"key":"4341_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611366","volume":"12","author":"Z Yan","year":"2021","unstructured":"Yan Z, Zhang H, Cao J et al (2021) Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol 12:611366. https:\/\/doi.org\/10.3389\/fimmu.2021.611366","journal-title":"Front Immunol"},{"key":"4341_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2023.01.030","volume":"184","author":"P Trinkner","year":"2023","unstructured":"Trinkner P, G\u00fcnther S, Monsef I, Kerschbaum E, von Bergwelt-Baildon M, Cordas Dos Santos DM, Theurich S (2023) Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy\u2014a systematic review and meta-analysis. Eur J Cancer 184:151\u2013171. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.030","journal-title":"Eur J Cancer"},{"key":"4341_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.annonc.2022.03.274","volume":"33","author":"UT Hacker","year":"2022","unstructured":"Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, Zdrazilova-Dubska L, Valik D, Lordick F (2022) Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol 33:685\u2013692. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.274","journal-title":"Ann Oncol"},{"key":"4341_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.Cir-22-0487","volume":"11","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Cordas Dos Santos DM, Parker NH et al (2023) Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy. Cancer Immunol Res 11:707\u2013719. https:\/\/doi.org\/10.1158\/2326-6066.Cir-22-0487","journal-title":"Cancer Immunol Res"},{"key":"4341_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/imt.15.12","volume":"7","author":"A Mirsoian","year":"2015","unstructured":"Mirsoian A, Murphy WJ (2015) Obesity and cancer immunotherapy toxicity. Immunotherapy 7:319\u2013322. https:\/\/doi.org\/10.2217\/imt.15.12","journal-title":"Immunotherapy"},{"key":"4341_CR35","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00262-021-02858-y","volume":"70","author":"Y You","year":"2021","unstructured":"You Y, Jiang C, Peng K, He W, Wang L, Jin Y, Xia L (2021) The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis. Cancer Immunol Immunother 70:2323\u20132335. https:\/\/doi.org\/10.1007\/s00262-021-02858-y","journal-title":"Cancer Immunol Immunother"},{"key":"4341_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111412","volume":"127","author":"J Yu","year":"2024","unstructured":"Yu J, Xiong F, Xu Y, Xu H, Zhang X, Gao H, Li Y (2024) Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor. Int Immunopharmacol 127:111412. https:\/\/doi.org\/10.1016\/j.intimp.2023.111412","journal-title":"Int Immunopharmacol"},{"key":"4341_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/d41586-018-05120-1","volume":"559","author":"DA Guertin","year":"2018","unstructured":"Guertin DA (2018) Unexpected cell population gives fat a brake. Nature 559:41\u201342. https:\/\/doi.org\/10.1038\/d41586-018-05120-1","journal-title":"Nature"},{"key":"4341_CR38","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.2337\/db11-0194","volume":"60","author":"YS Lee","year":"2011","unstructured":"Lee YS, Li P, Huh JY et al (2011) Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes 60:2474\u20132483. https:\/\/doi.org\/10.2337\/db11-0194","journal-title":"Diabetes"},{"key":"4341_CR39","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/jci19246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796\u20131808. https:\/\/doi.org\/10.1172\/jci19246","journal-title":"J Clin Invest"},{"key":"4341_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cmet.2016.03.002","volume":"23","author":"BC Lee","year":"2016","unstructured":"Lee BC, Kim MS, Pae M et al (2016) Adipose Natural Killer cells regulate adipose tissue macrophages to promote insulin resistance in obesity. Cell Metab 23:685\u2013698. https:\/\/doi.org\/10.1016\/j.cmet.2016.03.002","journal-title":"Cell Metab"},{"key":"4341_CR41","doi-asserted-by":"publisher","first-page":"11936","DOI":"10.1073\/pnas.1822067116","volume":"116","author":"I Hwang","year":"2019","unstructured":"Hwang I, Jo K, Shin KC et al (2019) GABA-stimulated adipose-derived stem cells suppress subcutaneous adipose inflammation in obesity. Proc Natl Acad Sci USA 116:11936\u201311945. https:\/\/doi.org\/10.1073\/pnas.1822067116","journal-title":"Proc Natl Acad Sci USA"},{"key":"4341_CR42","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154\u20135157. https:\/\/doi.org\/10.1182\/blood-2013-02-485623","journal-title":"Blood"},{"key":"4341_CR43","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 146:940\u2013948. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025","journal-title":"J Allergy Clin Immunol"},{"key":"4341_CR44","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1194\/jlr.M500294-JLR200","volume":"46","author":"S Cinti","year":"2005","unstructured":"Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347\u20132355. https:\/\/doi.org\/10.1194\/jlr.M500294-JLR200","journal-title":"J Lipid Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04341-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04341-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04341-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:05:37Z","timestamp":1773054337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04341-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4341"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04341-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of Peking University Cancer Hospital (2018YJZ75). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"96"}}